Send to

Choose Destination
Int Braz J Urol. 2003 Nov-Dec;29(6):517-9.

Complete response of metastatic renal cancer with dendritic cell vaccine.

Author information

Discipline of Urology, Paulista School of Medicine, Federal University of São Paulo, UNIFESP, Sírio Libanês Hospital of São Paulo and Department of Immunology, ICB-USP, São Paulo, SP, Brazil.



We report a case of metastatic renal cell carcinoma that presented involution following therapy with dendritic cells.


Male, 51-year old patient underwent left radical nephrectomy in September 1999 due to renal cell carcinoma, evolved with recurrence of the neoplasia in January 2002, confirmed by resection of the lesion. A vaccine therapy based on dendritic cells was then performed during 5 months (4 applications). After this period, there was occurrence of new lesions, whose resection revealed areas of necrosis and inflammatory infiltrate.


The outcome of renal cell carcinoma is influenced by prognostic factors that confer more aggressive tumor characteristics. However, in cases of recurrence, the systemic therapy with dendritic cells-based vaccine can be associated with a better outcome with regression of disease.

Free full text

Supplemental Content

Full text links

Icon for International Braz J Urol
Loading ...
Support Center